Medicamen Biotech Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, along with significant board-level changes. The pharmaceutical company's Board of Directors approved the results at a meeting held on February 13, 2026, while also addressing important governance matters.

Financial Performance Overview

The company's standalone financial performance for Q3 FY26 showed mixed results compared to the previous year. Net sales from operations reached ₹4,349.07 lakhs, representing growth from ₹4,114.23 lakhs in Q3 FY25. Total revenue, including other income, stood at ₹4,402.57 lakhs compared to ₹4,128.30 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, the company's performance showed a different trend. While revenue from operations declined slightly to ₹12,416.50 lakhs from ₹12,546.79 lakhs in the previous year, net profit decreased more significantly to ₹643.65 lakhs from ₹704.94 lakhs, representing a decline of approximately 8.70%.

Consolidated Results

On a consolidated basis, the company reported net profit of ₹163.47 lakhs for Q3 FY26 compared to ₹292.20 lakhs in Q3 FY25. Consolidated revenue from operations increased to ₹4,690.85 lakhs from ₹4,514.22 lakhs in the previous year quarter. The consolidated results include subsidiaries Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited.

Board Changes and Committee Reconstitution

A significant development during the quarter was the completion of tenure for two Independent Directors. Mr. Harish Pande (DIN: 01575625) and Mr. Arun Kumar (DIN: 07031730) ceased to be Independent Directors upon completion of two consecutive terms of 5 years each at the closure of business hours on February 13, 2026.

The Board approved the reconstitution of all major committees effective from February 13, 2026, to ensure continued compliance with governance requirements following the directors' tenure completion.

Operational Highlights

The company's cost structure showed some variations during the quarter. Cost of materials consumed decreased to ₹2,124.86 lakhs from ₹2,787.80 lakhs in Q3 FY25, while employee benefit expenses increased to ₹552.89 lakhs from ₹544.07 lakhs. Other expenses rose to ₹961.11 lakhs from ₹767.14 lakhs in the corresponding previous quarter.

The financial results were reviewed by statutory auditors Rai Qimat & Associates, Chartered Accountants, who provided limited review reports for both standalone and consolidated results. The company operates primarily in the pharmaceutical formulations segment and maintains its paid-up equity share capital at ₹1,356.28 lakhs with shares of ₹10 face value each.

Medicamen Biotech has announced that it has received European Union approval for the registration of paracetamol from Denmark in collaboration with XGX Pharma. This regulatory milestone marks an important development for the pharmaceutical company's international expansion strategy.

Regulatory Approval Details

The EU approval enables the company to market and distribute paracetamol products across European Union member states. The registration was obtained from Denmark, which serves as the reference member state for this particular pharmaceutical product.

Strategic Partnership

The collaboration with XGX Pharma demonstrates Medicamen Biotech's approach to leveraging strategic partnerships for regulatory approvals and market access. This partnership facilitates the company's entry into the European pharmaceutical market with its paracetamol formulation.

Market Implications

The EU approval provides Medicamen Biotech with access to one of the world's largest pharmaceutical markets. Paracetamol, being a widely used analgesic and antipyretic medication, represents a significant market opportunity across European territories. This regulatory success strengthens the company's pharmaceutical portfolio and enhances its competitive position in the international market.